Selected article for: "long term mortality and lung disease"
Author: Bari, Elia; Ferrarotti, Ilaria; Saracino, Laura; Perteghella, Sara; Torre, Maria Luisa; Richeldi, Luca; Corsico, Angelo Guido
Title: Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?
  • Cord-id: 2z44gpm1
  • Document date: 2021_5_14
    • ID: 2z44gpm1
    Snippet: To date, more than 100 million people worldwide have recovered from COVID-19. Unfortunately, although the virus is eradicated in such patients, fibrotic irreversible interstitial lung disease (pulmonary fibrosis, PF) is clinically evident. Given the vast numbers of individuals affected, it is urgent to design a strategy to prevent a second wave of late mortality associated with COVID-19 PF as a long-term consequence of such a devastating pandemic. Available antifibrotic therapies, namely ninteda
    Document: To date, more than 100 million people worldwide have recovered from COVID-19. Unfortunately, although the virus is eradicated in such patients, fibrotic irreversible interstitial lung disease (pulmonary fibrosis, PF) is clinically evident. Given the vast numbers of individuals affected, it is urgent to design a strategy to prevent a second wave of late mortality associated with COVID-19 PF as a long-term consequence of such a devastating pandemic. Available antifibrotic therapies, namely nintedanib and pirfenidone, might have a role in attenuating profibrotic pathways in SARS-CoV-2 infection but are not economically sustainable by national health systems and have critical adverse effects. It is our opinion that the mesenchymal stem cell secretome could offer a new therapeutic approach in treating COVID-19 fibrotic lungs through its anti-inflammatory and antifibrotic factors.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and lung architecture: 1, 2
    • acute ards respiratory distress syndrome and lung condition: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute phase and long term consequence: 1, 2, 3
    • acute phase and long term impairment: 1, 2, 3, 4, 5
    • acute phase and lung condition: 1
    • acute phase infection and long term impairment: 1
    • acute phase infection and lung condition: 1
    • acute respiratory syndrome and long term consequence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and long term impairment: 1, 2, 3, 4, 5
    • acute respiratory syndrome and low engraftment: 1
    • acute respiratory syndrome and lung architecture: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and lung condition: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25